Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt ...

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this ...

New and larger framework contract with the European Commission’s Health Emergency Preparedness and Response Authority (HERA) replaces previous agreement and provides for up to 8 million doses of ...

About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases.

The presentation will provide two-year follow-up data from the landmark BOOSTB4 Phase I/II clinical study. Notably, the results demonstrate that more than 50% of the treated patients experienced zero ...

Following the removal of the Caveat Emptor designation, Protext Mobility Inc. (OTC: TXTM) has entered a new phase of growth — one built on transparency, accountability, and leadership alignment.

The press release will be available in the Investors section of Cellectis’ website: Cellectis will not host a conference call to discuss these results. Our investors relations team remains available ...

RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the ...

Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET ...

In February 2025, Nxera Pharma announced that it had entered a license, supply and commercialization agreement with Holling Bio-Pharma Corp. for daridorexant in Taiwan.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will ...

Aficamten, omecamtiv mecarbil, ulacamten and CK-089 are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA ...